Izrael - hebrajski - Ministry of Health

neopharm (israel) 1996 ltd - fish oil; glucose monohydrate; glycine; l- alanine; l- isoleucine; l- lysine acetate; l- methionine; l- phenylalanine; l- proline; l- serine; l- threonine; l- tryptophan; l- tyrosine; l- valine; l-arginine; l-histidine; l-leucine; olive oil; soya bean oil, refined; taurine; triglycerides, medium-chain - תחליב לאינפוזיה - fish oil 30 g / 1000 ml; olive oil 50 g / 1000 ml; triglycerides, medium-chain 60 g / 1000 ml; soya bean oil, refined 60 g / 1000 ml; glucose monohydrate 462 g / 1000 ml; l- valine 6.2 g / 1000 ml; l- tyrosine 0.40 g / 1000 ml; l- tryptophan 2 g / 1000 ml; l- threonine 4.4 g / 1000 ml; taurine 1 g / 1000 ml; l- serine 6.5 g / 1000 ml; l- proline 11.2 g / 1000 ml; l- phenylalanine 5.1 g / 1000 ml; l- methionine 4.3 g / 1000 ml; l- lysine acetate 9.3 g / 1000 ml; l-leucine 7.4 g / 1000 ml; l- isoleucine 5 g / 1000 ml; l-histidine 3 g / 1000 ml; glycine 11 g / 1000 ml; l-arginine 12 g / 1000 ml; l- alanine 14 g / 1000 ml

Izrael - hebrajski - Ministry of Health

lapidot medical import and marketing ltd - acetyltyrosine 1.23 g/l; arginine 9.2 g/l - solution for infusion - solutions for parenteral nutrition - parenteral nutrition and fluid substitution prophylaxis and therapy of protein deficiency or increased protein needs.

Izrael - hebrajski - Ministry of Health

lapidot medical import and marketing ltd - acetylcysteine 0.68 g/l; acetyltyrosine 1.23 g/l - solution for infusion - solutions for parenteral nutrition - parenteral nutrition and fluid substitution prophylaxis and therapy of protein deficiency or increased protein needs.

Izrael - hebrajski - Ministry of Health

rafa laboratories ltd - naloxone hydrochloride (as dihydrate); oxycodone hydrochloride - טבליות בשחרור ממושך - naloxone hydrochloride (as dihydrate) 15 mg; oxycodone hydrochloride 30 mg - oxycodone and naloxone

Izrael - hebrajski - Ministry of Health

cts ltd - human fibrinogen; thrombin - sponge - thrombin 2 iu/cm2; human fibrinogen 5.5 mg/cm2 - human fibrinogen - human fibrinogen - tachosil is indicated for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing and for sutute support in vascular surgery where standard techniques are insufficient.

Izrael - hebrajski - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

Izrael - hebrajski - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 10 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

Izrael - hebrajski - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 2.5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

Izrael - hebrajski - Ministry of Health

abbvie biopharmaceuticals ltd, israel - upadacitinib as hemihydrate - טבליות בשחרור ממושך - upadacitinib as hemihydrate 15 mg - upadacitinib

Izrael - hebrajski - Ministry of Health

abbvie biopharmaceuticals ltd, israel - upadacitinib as hemihydrate - טבליות בשחרור ממושך - upadacitinib as hemihydrate 15 mg - upadacitinib